Key result
Puerarin significantly improved myocardial fibrosis and cardiac function in adriamycin-induced heart failure rats by inhibiting NHE1 activity and the p38 pathway.
Why the study?
The exact mechanism of puerarin's therapeutic and protective effect on cardiomyocytes in cardiovascular diseases remains unclear.
Does puerarin improve cardiac function and attenuate myocardial damage in an adriamycin-induced heart failure rat model?
Does puerarin improve cardiac function and attenuate myocardial damage in an adriamycin-induced heart failure rat model?
p-value: p=<0.05
Puerarin attenuates myocardial damage and improves cardiac function in a rat model of heart failure by inhibiting the p38 pathway and NHE1 activity.
Should not change HF practice; hypothesis-generating for NHE1/p38 inhibition in adriamycin models.
Previous studies have shown that puerarin plays a key role in protecting humans and animals from cardiovascular diseases. The exact mechanism of the therapeutic effect of puerarin on various cardiovascular diseases (protective effect on cardiomyocytes) is still unclear. In the present study, we identify the role of puerarin in an animal model of experimental heart failure (HF) and explore its underlying mechanisms. The HF rat model is induced by intraperitoneal injection of adriamycin (ADR), and puerarin is administered intragastrically at low, medium, and high concentrations. We demonstrate that puerarin significantly improves myocardial fibrosis and inflammatory infiltration and, as a result, improves cardiac function in ADR-induced HF rats. Mechanistically, we find for the first time that puerarin inhibits overactivated Na⁺/H⁺ exchange isoform 1 (NHE1) in HF, which may improve HF by decreasing Na⁺ and Ca²⁺ ion concentrations and attenuating mitochondrial damage caused by calcium overload; on the other hand, puerarin inhibits the activation of the p38 pathway in HF, reduces the expressions of TGF-β and proinflammatory cytokines, and suppresses myocardial fibrosis. In conclusion, our results suggest that Puerarin is an effective drug against HF and may play a protective role in the myocardium by inhibiting the activation of p38 and its downstream NHE1.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2023) studied Heart failure (n=40). Puerarin vs. Adriamycin (ADR) alone was evaluated on Cardiac function (Ejection Fraction) and myocardial fibrosis (p=<0.05). Puerarin significantly improved myocardial fibrosis and cardiac function in adriamycin-induced heart failure rats by inhibiting NHE1 activity and the p38 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: